Gramicidin S
Overview
Gramicidin S is a cyclic decapeptide antibiotic isolated from Bacillus brevis, consisting of two identical pentapeptide sequences joined in a ring structure. The peptide exerts antimicrobial activity by disrupting bacterial cell membrane integrity through interaction with phospholipid bilayers, leading to leakage of cellular contents. Its amphipathic beta-sheet conformation enables selective insertion into bacterial membranes. The compound demonstrates broad-spectrum activity against both Gram-positive and Gram-negative organisms.
Key Research Findings
Gramicidin S has been used primarily as a topical antimicrobial agent in certain countries, particularly in the former Soviet Union, but is not FDA approved for systemic use due to hemolytic toxicity and nephrotoxicity. In vitro studies have confirmed potent activity against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Staphylococcus aureus. Current research focuses on structural analogs with improved therapeutic indices for potential topical or surface decontamination applications.
Topical
Investigational
Interested in Gramicidin S?
Find a verified provider experienced with Gramicidin S protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Gramicidin S ProviderRelated Peptides
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fusion step. Enfuvirtide binds to the first heptad repeat (HR1) region of gp41, preventing the conformational change required for viral-cell membrane fusion. It is the first and only FDA-approved fusion inhibitor and is active against HIV-1 strains resistant to other antiretroviral drug classes.
Magainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells. Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens.
Pexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic stability. It disrupts bacterial membranes through electrostatic interaction and pore formation, demonstrating broad-spectrum activity against gram-positive and gram-negative organisms, including methicillin-resistant Staphylococcus aureus. Pexiganan was developed as a topical agent for infected diabetic foot ulcers, leveraging its rapid bactericidal action and low resistance potential. Structural modifications from the parent magainin sequence improve its pharmacological profile for clinical use.
Omiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring peptide from bovine neutrophils. It acts by disrupting microbial membranes and demonstrates activity against bacteria, fungi, and some viruses. Omiganan was developed as a topical agent to prevent catheter-related bloodstream infections through its broad-spectrum antimicrobial properties. Its small size and potent activity made it a candidate for preventing biofilm formation on medical devices.